Supplementary Table S11 from Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial Petros Grivas , Elena Garralda , Funda Meric-Bernstam , Ingo K. Mellinghoff , Lipika Goyal , James J. Harding , E. Claire Dees , Rastislav Bahleda , Nilofer S. Azad , Asha Karippot , Razelle Kurzrock , Josep Tabernero , Juha Kononen , Matthew C.H. Ng , Rutika Mehta , Nataliya V. Uboha , Frédéric Bigot , Valentina Boni , Samantha E. Bowyer , Valeriy Breder , Andrés Cervantes , Nancy Chan , James M. Cleary , Mallika Dhawan , Rikke L. Eefsen , James Ewing , Donna M. Graham , Tormod K. Guren , Jin Won Kim , Krassimir Koynov , Do-Youn Oh , Rebecca Redman , Chia-Jui Yen , David Spetzler , Marie-Claude Roubaudi-Fraschini , Valerie Nicolas-Metral , Rafik Ait-Sarkouh , Claudio Zanna , Abdallah Ennaji , Anna Pokorska-Bocci , Keith T. Flaherty crossref（2024）
摘要
Supplementary Table S11. Treatment-emergent adverse events occurring at grade ≥3 in ≥2 patients (safety population).
更多 查看译文
AI 理解论文
溯源树
样例
